07:18 AM EST, 11/10/2025 (MT Newswires) -- Ionis Pharmaceuticals ( IONS ) said over the weekend that two phase 3 studies of olezarsen in people with severe hypertriglyceridemia met the primary endpoint.

The drug reduced fasting triglyceride levels by up to 72% at six months, and 86% of treated patients achieved triglyceride levels below the risk threshold for acute pancreatitis, Ionis said, adding that the reductions were sustained through 12 months.

The drug, currently approved as Tryngolza to treat familial chylomicronemia syndrome, also demonstrated a favorable safety and tolerability profile in severe hypertriglyceridemia, the company said.

Ionis said it is on track to submit a supplemental new drug application in the US by the end of 2025.

Shares of Ionis were down more than 12% in recent premarket activity Monday.